DE2506099C2 - Sulfonamid und Trimethoprim enthaltende Tablette - Google Patents
Sulfonamid und Trimethoprim enthaltende TabletteInfo
- Publication number
- DE2506099C2 DE2506099C2 DE2506099A DE2506099A DE2506099C2 DE 2506099 C2 DE2506099 C2 DE 2506099C2 DE 2506099 A DE2506099 A DE 2506099A DE 2506099 A DE2506099 A DE 2506099A DE 2506099 C2 DE2506099 C2 DE 2506099C2
- Authority
- DE
- Germany
- Prior art keywords
- tablet
- trimethoprim
- weight
- tablets
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 title claims description 26
- 229960001082 trimethoprim Drugs 0.000 title claims description 26
- 229940124530 sulfonamide Drugs 0.000 title claims description 17
- 150000003456 sulfonamides Chemical class 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 claims description 27
- 239000007884 disintegrant Substances 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 230000008961 swelling Effects 0.000 claims description 12
- 239000003979 granulating agent Substances 0.000 claims description 6
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 description 25
- 239000008187 granular material Substances 0.000 description 18
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 229960005404 sulfamethoxazole Drugs 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000005299 abrasion Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 235000010443 alginic acid Nutrition 0.000 description 8
- 229920000615 alginic acid Polymers 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229920003110 Primojel Polymers 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 229920003109 sodium starch glycolate Polymers 0.000 description 5
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 4
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 3
- -1 4-aminobenzenesulfonamido Chemical group 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000002360 explosive Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940071117 starch glycolate Drugs 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940047766 co-trimoxazole Drugs 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LSBIUXKNVUBKRI-UHFFFAOYSA-N 4,6-dimethylpyrimidine Chemical compound CC1=CC(C)=NC=N1 LSBIUXKNVUBKRI-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical class NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB6758/74A GB1499672A (en) | 1974-02-14 | 1974-02-14 | Tablet formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2506099A1 DE2506099A1 (de) | 1975-08-21 |
| DE2506099C2 true DE2506099C2 (de) | 1983-11-03 |
Family
ID=9820242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2506099A Expired DE2506099C2 (de) | 1974-02-14 | 1975-02-13 | Sulfonamid und Trimethoprim enthaltende Tablette |
Country Status (32)
| Country | Link |
|---|---|
| JP (1) | JPS5545043B2 (en, 2012) |
| AT (1) | AT344915B (en, 2012) |
| AU (1) | AU468465B2 (en, 2012) |
| BE (1) | BE825496A (en, 2012) |
| CA (1) | CA980688A (en, 2012) |
| CH (1) | CH618432A5 (en, 2012) |
| CS (1) | CS220306B2 (en, 2012) |
| CY (1) | CY1052A (en, 2012) |
| DD (1) | DD118228A5 (en, 2012) |
| DE (1) | DE2506099C2 (en, 2012) |
| DK (1) | DK143247C (en, 2012) |
| DO (1) | DOP1979002763A (en, 2012) |
| ES (1) | ES434688A1 (en, 2012) |
| FI (1) | FI62219C (en, 2012) |
| FR (1) | FR2260993B1 (en, 2012) |
| GB (1) | GB1499672A (en, 2012) |
| GT (1) | GT197960431A (en, 2012) |
| HK (1) | HK23980A (en, 2012) |
| HU (1) | HU171536B (en, 2012) |
| IE (1) | IE40599B1 (en, 2012) |
| IL (1) | IL46629A (en, 2012) |
| IN (1) | IN141019B (en, 2012) |
| KE (1) | KE3038A (en, 2012) |
| LU (1) | LU71835A1 (en, 2012) |
| MC (1) | MC1053A1 (en, 2012) |
| MY (1) | MY8100054A (en, 2012) |
| NL (1) | NL157501C (en, 2012) |
| NO (1) | NO146043C (en, 2012) |
| PH (1) | PH14575A (en, 2012) |
| SE (1) | SE427898B (en, 2012) |
| ZA (1) | ZA75930B (en, 2012) |
| ZM (1) | ZM1875A1 (en, 2012) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1533243A (en) * | 1975-02-13 | 1978-11-22 | Wellcome Found | Tablet formulation |
| US4115563A (en) * | 1977-03-14 | 1978-09-19 | Sterling Drug Inc. | Pharmaceutical steroid formulation |
| GB1601833A (en) * | 1978-02-06 | 1981-11-04 | Wellcome Found | Antacid formulation |
| HU183408B (en) | 1981-04-28 | 1984-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing oral ratard pharmaceutical compositions |
| GB8603964D0 (en) * | 1986-02-18 | 1986-03-26 | Cooper Animal Health Ltd | Compositions |
| US5190760A (en) * | 1989-07-08 | 1993-03-02 | Coopers Animal Health Limited | Solid pharmaceutical composition |
| GB8915716D0 (en) * | 1989-07-08 | 1989-08-31 | Coopers Animal Health | Pharmaceutical compositions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1445983A (en) * | 1972-11-06 | 1976-08-11 | Wellcome Found | Pharmaceutical formulations |
-
1974
- 1974-02-14 GB GB6758/74A patent/GB1499672A/en not_active Expired
-
1975
- 1975-02-13 FI FI750398A patent/FI62219C/fi not_active IP Right Cessation
- 1975-02-13 FR FR7504470A patent/FR2260993B1/fr not_active Expired
- 1975-02-13 DE DE2506099A patent/DE2506099C2/de not_active Expired
- 1975-02-13 IE IE278/75A patent/IE40599B1/xx unknown
- 1975-02-13 SE SE7501595A patent/SE427898B/xx not_active IP Right Cessation
- 1975-02-13 IN IN270/CAL/75A patent/IN141019B/en unknown
- 1975-02-13 NO NO750467A patent/NO146043C/no unknown
- 1975-02-13 HU HU75WE00000519A patent/HU171536B/hu unknown
- 1975-02-13 CY CY1052A patent/CY1052A/xx unknown
- 1975-02-13 LU LU71835A patent/LU71835A1/xx unknown
- 1975-02-13 DK DK52875A patent/DK143247C/da not_active IP Right Cessation
- 1975-02-13 JP JP1838875A patent/JPS5545043B2/ja not_active Expired
- 1975-02-13 IL IL46629A patent/IL46629A/en unknown
- 1975-02-13 PH PH16805A patent/PH14575A/en unknown
- 1975-02-13 AT AT108475A patent/AT344915B/de not_active IP Right Cessation
- 1975-02-13 CA CA219,982A patent/CA980688A/en not_active Expired
- 1975-02-13 CH CH174775A patent/CH618432A5/de not_active IP Right Cessation
- 1975-02-13 ZM ZM18/75A patent/ZM1875A1/xx unknown
- 1975-02-13 AU AU78170/75A patent/AU468465B2/en not_active Expired
- 1975-02-13 BE BE153330A patent/BE825496A/xx not_active IP Right Cessation
- 1975-02-13 ZA ZA00750930A patent/ZA75930B/xx unknown
- 1975-02-13 ES ES434688A patent/ES434688A1/es not_active Expired
- 1975-02-13 DD DD184168A patent/DD118228A5/xx unknown
- 1975-02-13 CS CS75927A patent/CS220306B2/cs unknown
- 1975-02-13 MC MC751136A patent/MC1053A1/xx unknown
- 1975-02-13 NL NL7501680.A patent/NL157501C/xx not_active IP Right Cessation
-
1979
- 1979-05-14 DO DO1979002763A patent/DOP1979002763A/es unknown
- 1979-11-12 GT GT197960431A patent/GT197960431A/es unknown
-
1980
- 1980-03-28 KE KE3038A patent/KE3038A/xx unknown
- 1980-05-01 HK HK239/80A patent/HK23980A/xx unknown
-
1981
- 1981-12-30 MY MY54/81A patent/MY8100054A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3688674T2 (de) | Hydroxypropylcelluloseether enthaltende Mittel mit verzögerter Wirkstoffabgabe. | |
| DE3880762T2 (de) | Orale, acetaminophen enthaltende zusammensetzung mit gesteuerter arzneistoff-freisetzung und verfahren zu ihrer herstellung. | |
| DE68916983T2 (de) | Verfahren zur Herstellung eines pharmazeutischen Granulats. | |
| DE3877764T2 (de) | Ein freifliessendes granulat, enthaltend ibuprofen und ein herstellunsgverfahren. | |
| DE60316552T2 (de) | Tablette mit hohem wirkstoffgehalt | |
| DE69400356T2 (de) | Quervernetzte amylose als bindemittel/sprengmittel fuer tabletten | |
| DE3780056T2 (de) | Verfahren zur herstellung von arzneimittelformulierungen mit gesteuerter und verlaengerter wirkung in einzeldosisform mit einheitlichen und vergleichbaren bioverfuegbarkeitscharakteristika. | |
| DE69530421T2 (de) | Stärkeacetatpräparat mit modifizierbaren eigenschaften, verfahren für seine herstellung und verwendung | |
| DE2553239A1 (de) | Verfahren zur herstellung von niedrig substituierten zelluloseaethern | |
| DE3650716T2 (de) | Trimethoprim und ein Sulfonamid enthaltende Tabletten | |
| DE60224056T2 (de) | Antazide und laxative magnesiumoxid-tablette | |
| US4209513A (en) | Tablet formulation | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE60103247T2 (de) | Verfahren zur Herstellung von Formulierungen zur Direkttablettierung | |
| DE2506099C2 (de) | Sulfonamid und Trimethoprim enthaltende Tablette | |
| DE2200778B2 (de) | Verwendung von hochmolekularem, unlöslichem, quervernetztem Polyvinylpyrrolidon als Sprengmittel in festen Arzneiformen | |
| DE60129515T2 (de) | Basismaterial zur trockenen Direkttablettierung enthaltend niedrig substituierte Hydroxypropylcellulose | |
| DE1492253A1 (de) | Verfahren zur Herstellung von Tabletten mit protrahierter Wirkung | |
| DE3150557C2 (en, 2012) | ||
| EP0414115A1 (de) | Hilfsmittelfreie Riboflavingranulate | |
| EP0537139B1 (de) | Verfahren zur herstellung geformter, verpresster dosiseinheiten mit retardierter freisetzung und entsprechende dosiseinheit | |
| DE60005469T2 (de) | Arzneizusammensetzung enthaltend Ascorbinsäure und Pektin | |
| DE2050701C3 (de) | Verwendung eines pulverförmigen Celluloseäthers als Hilfsstoff zur Herstellung von leicht zerfallbaren festen Arzneiformen | |
| DE60206940T2 (de) | Pektin und ascorbinsäure enthaltende zusammensetzungen | |
| DE68907609T2 (de) | Arzneimittelzusammensetzung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8181 | Inventor (new situation) |
Free format text: TORODE, ALLAN JOHN, BASILDON, ESSEX, GB HARDEN, DAVID, SIDCUP, KENT, GB SPENCE, JOHN, BICKLEY, KENT, GB |
|
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: BERG, W., DIPL.-CHEM. DR.RER.NAT. SCHWABE, H., DIPL.-ING. SANDMAIR, K., DIPL.-CHEM. DR.JUR. DR.RER.NAT., PAT.-ANW., 8000 MUENCHEN |
|
| 8365 | Fully valid after opposition proceedings | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: SCHWABE, H., DIPL.-ING. SANDMAIR, K., DIPL.-CHEM. DR.JUR. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN |
|
| 8310 | Action for declaration of annulment | ||
| 8311 | Complete invalidation |